NCT05323955 - Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 23, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

July 31, 2026

Conditions

Brain MetastasesHuman Epidermal Growth Factor 2 Positive Carcinoma of BreastAdvanced Breast Cancer

Interventions

DRUG

Trastuzumab

Administer per current package insert based on site standard of care guidelines

DRUG

Trastuzumab Emtansine (T-DM1)

Administer per current package insert based on site standard of care guidelines

DRUG

Pertuzumab

Administer per current package insert based on site standard of care guidelines

DRUG

Tucatinib

300 mg orally twice daily (21 Day Cycle)

Trial Locations (8)

Duke University Medical Center, Durham

Ohio State University Comprehensive Cancer Center, Columbus

University of Michigan Health System, Ann Arbor

Washington University in St. Louis, St Louis

MD Anderson Cancer Center, Houston

University of California San Francisco, San Francisco

Providence Portland Medical Center, Portland

Dana Farber Cancer Institute, Boston